Huaren Pharmaceutical Co., Ltd. (300110.SZ)
CNY 2.9
(3.2%)
CNY 2.9
(3.2%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.64 Billion CNY | -3.04% |
| 2022 | 1.7 Billion CNY | 5.48% |
| 2021 | 1.61 Billion CNY | 423.64% |
| 2020 | 307.98 Million CNY | 273.79% |
| 2019 | -177.21 Million CNY | -277.63% |
| 2018 | 99.76 Million CNY | -87.8% |
| 2017 | 817.62 Million CNY | -1.24% |
| 2016 | 827.89 Million CNY | -6.83% |
| 2015 | 888.55 Million CNY | 38.26% |
| 2014 | 642.65 Million CNY | 112.72% |
| 2013 | 302.12 Million CNY | 189.54% |
| 2012 | 104.34 Million CNY | 134.12% |
| 2011 | -305.79 Million CNY | 35.11% |
| 2010 | -471.26 Million CNY | -294.56% |
| 2009 | 242.21 Million CNY | 20.84% |
| 2008 | 200.44 Million CNY | 65.31% |
| 2007 | 121.26 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 1.47 Billion CNY | -43.75% |
| 2024 Q1 | 1.57 Billion CNY | -4.58% |
| 2024 Q2 | 1.54 Billion CNY | -2.11% |
| 2023 Q1 | 1.65 Billion CNY | -2.54% |
| 2023 FY | 1.64 Billion CNY | -3.04% |
| 2023 Q2 | 1.75 Billion CNY | 6.01% |
| 2023 Q3 | 1.73 Billion CNY | -1.0% |
| 2023 Q4 | 1.64 Billion CNY | -5.21% |
| 2022 Q2 | 1.84 Billion CNY | 9.11% |
| 2022 Q4 | 1.7 Billion CNY | -4.27% |
| 2022 FY | 1.7 Billion CNY | 5.48% |
| 2022 Q3 | 1.77 Billion CNY | -3.62% |
| 2022 Q1 | 1.68 Billion CNY | 4.79% |
| 2021 Q3 | 1.37 Billion CNY | 37.48% |
| 2021 Q1 | 561.02 Million CNY | 82.16% |
| 2021 Q2 | 996.72 Million CNY | 77.66% |
| 2021 Q4 | 1.61 Billion CNY | 17.69% |
| 2021 FY | 1.61 Billion CNY | 423.64% |
| 2020 FY | 307.98 Million CNY | 273.79% |
| 2020 Q3 | -228.45 Million CNY | 0.66% |
| 2020 Q2 | -229.96 Million CNY | 7.33% |
| 2020 Q4 | 307.98 Million CNY | 234.81% |
| 2020 Q1 | -248.14 Million CNY | -40.03% |
| 2019 FY | -177.21 Million CNY | -277.63% |
| 2019 Q3 | -10.43 Million CNY | -112.75% |
| 2019 Q4 | -177.21 Million CNY | -1597.74% |
| 2019 Q1 | 127.35 Million CNY | 27.66% |
| 2019 Q2 | 81.87 Million CNY | -35.71% |
| 2018 Q4 | 99.76 Million CNY | 7.92% |
| 2018 FY | 99.76 Million CNY | -87.8% |
| 2018 Q1 | 176.21 Million CNY | -78.45% |
| 2018 Q2 | 119.07 Million CNY | -32.43% |
| 2018 Q3 | 92.43 Million CNY | -22.37% |
| 2017 Q4 | 817.62 Million CNY | 7.39% |
| 2017 FY | 817.62 Million CNY | -1.24% |
| 2017 Q3 | 761.39 Million CNY | -0.41% |
| 2017 Q2 | 764.5 Million CNY | 3.78% |
| 2017 Q1 | 736.69 Million CNY | -11.02% |
| 2016 FY | 827.89 Million CNY | -6.83% |
| 2016 Q4 | 827.89 Million CNY | 7.73% |
| 2016 Q3 | 768.49 Million CNY | -13.62% |
| 2016 Q2 | 889.71 Million CNY | 8.03% |
| 2016 Q1 | 823.55 Million CNY | -7.31% |
| 2015 FY | 888.55 Million CNY | 38.26% |
| 2015 Q1 | 789 Million CNY | 22.77% |
| 2015 Q2 | 893.15 Million CNY | 13.2% |
| 2015 Q3 | 922.08 Million CNY | 3.24% |
| 2015 Q4 | 888.55 Million CNY | -3.64% |
| 2014 Q1 | 355.04 Million CNY | 17.52% |
| 2014 FY | 642.65 Million CNY | 112.72% |
| 2014 Q3 | 565.45 Million CNY | 11.83% |
| 2014 Q2 | 505.63 Million CNY | 42.41% |
| 2014 Q4 | 642.65 Million CNY | 13.65% |
| 2013 Q3 | 258.9 Million CNY | 30.23% |
| 2013 Q4 | 302.12 Million CNY | 16.69% |
| 2013 FY | 302.12 Million CNY | 189.54% |
| 2013 Q1 | 170.05 Million CNY | 62.97% |
| 2013 Q2 | 198.8 Million CNY | 16.91% |
| 2012 Q1 | -296.01 Million CNY | 3.2% |
| 2012 Q4 | 104.34 Million CNY | 35.24% |
| 2012 FY | 104.34 Million CNY | 134.12% |
| 2012 Q3 | 77.15 Million CNY | 150.33% |
| 2012 Q2 | -153.3 Million CNY | 48.21% |
| 2011 Q1 | -467.29 Million CNY | 0.84% |
| 2011 FY | -305.79 Million CNY | 35.11% |
| 2011 Q3 | -364.68 Million CNY | 14.63% |
| 2011 Q2 | -427.17 Million CNY | 8.59% |
| 2011 Q4 | -305.79 Million CNY | 16.15% |
| 2010 Q2 | 253.17 Million CNY | 0.0% |
| 2010 Q4 | -471.26 Million CNY | -3.41% |
| 2010 Q3 | -455.73 Million CNY | -280.01% |
| 2010 FY | -471.26 Million CNY | -294.56% |
| 2009 Q4 | 242.21 Million CNY | 0.0% |
| 2009 FY | 242.21 Million CNY | 20.84% |
| 2008 FY | 200.44 Million CNY | 65.31% |
| 2007 FY | 121.26 Million CNY | 0.0% |